ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company's sticky, essential products and expanding digital platform create a powerful, recession-resistant business model with strong secular tailwinds. We forecast 10% compound annual growth through 2030, with shares offering 13-21% upside based on reasonable valuation multiples and robust earnings growth.
ResMed (RMD) reported earnings 30 days ago. What's next for the stock?
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
Medical - Instruments & Supplies Industry | Healthcare Sector | Mr. Michael J. Farrell BE, MBA, SM CEO | XMUN Exchange | US7611521078 ISIN |
US Country | 10,140 Employees | 13 Feb 2025 Last Dividend | 31 Aug 2010 Last Split | 2 Jun 1995 IPO Date |
ResMed Inc. is a pioneering company focused on developing, manufacturing, distributing, and marketing medical devices alongside cloud-based software applications tailored for the healthcare markets. With its operational base divided between Sleep and Respiratory Care, and Software as a Service (SaaS), ResMed is at the forefront of offering innovative solutions for managing respiratory disorders. The company's extensive product lineup and software solutions cater to both medical and consumer needs, aiming to improve patient outcomes through advanced technology and connectivity. Founded in 1989 and headquartered in San Diego, California, ResMed markets its products globally through a combination of direct sales forces and a network of distributors, targeting sleep clinics, home healthcare dealers, and hospitals.